Spots Global Cancer Trial Database for Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity
Official Title: Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity Following CAR-T Infusion on an Outpatient Basis
Study ID: NCT04503538
Interventions
Study Description
Brief Summary: The purpose of this research is to replace one of participants' outpatient chimeric antigen receptor T-cell (CAR-T) therapy follow up visits with a virtual or "telemedicine" visit. The telemedicine visit will use an electronic tablet with a camera and a microphone that allows participants to communicate with their physicians and nurses. Participants will be provided with the necessary equipment to complete these visits.
Detailed Description: Primary Objective: To determine feasibility of telemedicine for outpatient cytokine release syndrome and neurotoxicity assessment (how many telemedicine visits successfully completed per patient) Secondary Objective(s) * To determine how many times a telemedicine visit triggered an action (inpatient admission/ outpatient observation status) * To determine how many patients were detected to have cytokine release syndrome and/or neurotoxicity based on their telemedicine visit
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Contact Details
Name: Rakhee Vaidya, MBBS
Affiliation: Wake Forest University Health Sciences
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
